BCR and chronic myelogenous leukemia, BCR-ABL1 positive: QLT-0267 has been previously described [11,31] as a specific inhibitor of ILK [32,33] and imatinib, is an FDA-approved ABL1 tyrosine kinase inhibitor that targets the constitutive tyrosine kinase activity of BCR-ABL in chronic myelogenous leukemia.